A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

被引：25

作者：

Siegel, David ^{[1
]}

Jagannath, Sundar ^{[1
]}

Vesole, David H. ^{[1
]}

Borello, Ivan ^{[2
]}

Mazumder, Amitabha ^{[1
]}

Mitsiades, Constantine ^{[3
]}

Goddard, Jill ^{[4
]}

Dunbar, Joi ^{[4
]}

Normant, Emmanuel ^{[4
]}

Adams, Julian ^{[4
]}

Grayzel, David ^{[4
]}

Anderson, Kenneth C. ^{[3
]}

Richardson, Paul ^{[3
]}

机构：

[1] Hackensack Univ Med Ctr, Hackensack, NJ 07601 USA

[2] Johns Hopkins, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Infin Pharmaceut Inc, Cambridge, MA USA

来源：

LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 12期

关键词：

Multiple myeloma; HSP90; IPI-504; phase; 1; relapsed/refractory; UNFOLDED PROTEIN RESPONSE; I TRIAL; CHAPERONE; INHIBITORS; HSP90; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; HEAT-SHOCK-PROTEIN-90; 17-ALLYLAMINO; GELDANAMYCIN;

D O I：

10.3109/10428194.2011.600481

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered intravenously twice weekly for 2 weeks at 22.5, 45, 90, 150, 225, 300 or 400 mg/m(2) followed by 10 days off-treatment was conducted to determine the safety and maximum tolerated dose (MTD) of IPI-504 in patients with relapsed or relapsed/refractory multiple myeloma (MM). Anti-tumor activity and pharmacokinetics were also evaluated. Eighteen patients (mean age 60.5 years; median 9 prior therapies) were enrolled. No dose-limiting toxicities (DLTs) were reported for IPI-504 doses up to 400 mg/m(2). The most common treatment-related adverse event was grade 1 infusion site pain (four patients). All other treatment-related events were assessed as grade 1 or 2 in severity. The area under the curve (AUC) increased with increasing dose, and the mean half-life was approximately 2-4 h for IPI-504 and its metabolites. Four patients had stable disease, demonstrating modest single-agent activity in relapsed or relapsed/refractory MM.

引用

页码：2308 / 2315

页数：8

共 29 条

[1] Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models [J].